The latest clinical results of Kangfang BioPD-1/CTLA-4 dual anti-latest clinical results were released

Cadonilimab, a new, potential next-generation first-in-class PD-1/CTLA-4 dual resistance developed by Kangfang Bio, has demonstrated the clinical efficacy of PD-1 and CTLA-4 monoclonal antibody combination therapies and the good safety that PD-1 and CTLA-4 monoclonal antibody combination therapies cannot provide.
the study published today shows that as of November 2020, the objective remission rate (ORR) was 64.1% and the disease control rate (DCR) was 87.2% among assessable GC or GEJ patients receiving Cadonilimab combined with Oxali platinum and Caperthalina first-line treatment.
follow-up time was 8.0 months for patients with a 4 mg-kg queue, the medium remission duration (DOR) was not reached, and the 6-month progression-free survival rate was 76.5%.
of the 10 mg/kg queue patients in the group, 3 were partially relieved (75%) and 1 target lesions were reduced by 22% and are still being evaluated for treatment.
results from the study showed that the risk of level 3 and above adverse reactions associated with Cadonilimab or chemotherapy was 38.9%, of which the risk of immune-related adverse reactions at level 3 and above was 7.4%.
, a Phase III study of Cadonilimab's combined chemotherapy first-line treatment GC or GEJ is currently under planning, according to a health announcement.
major adaptations to the Cadonilimab layout include liver cancer, cervical cancer, lung cancer, esophageal squamous cancer and nasopharyngeal cancer.
Details of Clinical Development of Cardonilimab Adaptations from insight database ()